Their more recent work has clarified the NOTCH-mutant cases as part of an ACC-I subclass that collectively demonstrate upregulation of other hyperactivating genes such as MYC and BCL2, which describes an estimated 37% of all ACC tumors (15). This evidence concerns the gene MYC and adrenal cortex carcinoma.